Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[PPAR gamma agonist and antagonist].

T Kadowaki1

  • 1Department of Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan. kadowaki-3im@h.u-tokyo.ac.jp

Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
|December 4, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcription factor EB influences invasion and migration in oral squamous cell carcinomas.

Oral diseases·2018
Same author

Lactic acidosis due to attempted suicide with metformin overdose: A case report.

Diabetes & metabolism·2016
Same author

Coping strategies and risk of cardiovascular disease incidence and mortality: the Japan Public Health Center-based prospective Study.

European heart journal·2016
Same author

A case of insulin allergy successfully managed using multihexamer-forming insulin degludec combined with liraglutide.

Diabetic medicine : a journal of the British Diabetic Association·2015
Same author

A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.

Diabetes, obesity & metabolism·2015
Same author

Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance.

Diabetes, obesity & metabolism·2015
Same journal

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Prediction of severe oral mucositis in cancer treatment: the role of the oral-gut axis in precision supportive care].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Iron dysregulation and ferroptosis in heart failure: the dual faces of deficiency and overload].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Pharmacological characteristics and clinical outcomes of Rimegepant (Nurtec<sup>®</sup> ODT), an oral CGRP receptor antagonist for the acute treatment and prevention of migraine].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Pharmacological properties and clinical trial results of datopotamab deruxtecan (Dato-DXd, Datroway<sup>®</sup>)].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Oxytocin regulates social familiarity-dependent mate choice in medaka].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
See all related articles

Moderate antagonism of Peroxisome proliferator-activated receptor gamma (PPAR gamma) and retinoid X receptor (RXR) can treat obesity and type 2 diabetes by reducing fat and improving insulin sensitivity.

Area of Science:

  • Endocrinology
  • Metabolic disease research
  • Molecular biology

Context:

  • Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a nuclear receptor involved in glucose and lipid metabolism.
  • PPAR gamma agonists like thiazolidinediones treat type 2 diabetes but cause weight gain.
  • Moderate PPAR gamma deficiency protects against high-fat diet-induced obesity and insulin resistance.

Purpose:

  • To investigate if functional antagonism of the PPAR gamma/retinoid X receptor (RXR) complex can treat obesity and type 2 diabetes.
  • To determine the effects of moderate versus severe PPAR gamma reduction on metabolic parameters.

Summary:

  • Moderate reduction of PPAR gamma/RXR activity using antagonists decreased triglyceride content in adipose tissue, muscle, and liver.

Related Experiment Videos

  • These antagonists enhanced leptin and adiponectin levels, increasing fatty acid combustion and energy expenditure, thus ameliorating obesity and insulin resistance.
  • Severe PPAR gamma reduction led to fat depletion, decreased leptin and adiponectin, and re-emergent insulin resistance.

    • Impact:

    • Functional antagonism of PPAR gamma/RXR offers a potential therapeutic strategy for obesity and type 2 diabetes.
    • The findings highlight the importance of a moderate level of PPAR gamma activity for metabolic health.
    • This research provides a basis for developing novel drugs targeting the PPAR gamma/RXR pathway.